Meletios Therapeutics is a biotech company that develops antiviral molecules for unmet emergency medical needs.
Meletios Therapeutics has raised $2.6M in total funding. The most recent round was Private Equity. The last funding was announced in November 2022.
Meletios Therapeutics's investors include European Innovation Council.
Meletios Therapeutics is headquartered in Lyon, France.
Meletios Therapeutics is a biotech company that develops antiviral molecules for unmet emergency medical needs.
Meletios Therapeutics is at the Private Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Meletios Therapeutics — Funding & Investors." VCBacked, November 2, 2022, https://www.vcbacked.co/company/meletios-therapeutics. Accessed October 30, 2026.
VCBacked. (2022). Meletios Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/meletios-therapeutics
{{cite web |title=Meletios Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/meletios-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated